Nasal antihistamines and decongestants

I. Introduction

Nasal antihistamines and decongestants are topical medications administered intranasally to alleviate symptoms of allergic rhinitis, non-allergic rhinitis, sinusitis, and upper respiratory tract infections. These medications act locally on the nasal mucosa to reduce inflammation, suppress allergic responses, or induce vasoconstriction, thereby offering rapid and effective symptom control.

Nasal antihistamines and decongestants are available both as standalone formulations and in combination products, commonly delivered as sprays or drops. Due to their topical mode of action, they offer faster relief and fewer systemic side effects compared to oral counterparts.

---

II. Nasal Antihistamines

A. Mechanism of Action
Nasal antihistamines are H1 receptor antagonists that block histamine activity in the nasal mucosa. Histamine is a key mediator in allergic reactions, causing sneezing, rhinorrhea, and nasal itching. By inhibiting H1 receptors locally, nasal antihistamines provide direct and rapid relief from allergy symptoms.

B. Common Active Ingredients

1. Azelastine hydrochloride

2. Olopatadine hydrochloride

3. Levocabastine (less commonly used today)

C. Clinical Uses

• Seasonal allergic rhinitis (SAR)

• Perennial allergic rhinitis (PAR)

• Non-allergic rhinitis with eosinophilia syndrome (NARES)

• Vasomotor rhinitis

D. Pharmacokinetics

• Onset: ~15 minutes after administration

• Duration: 12–24 hours depending on formulation

• Bioavailability: Some systemic absorption (~40% for azelastine)

• Metabolism: Hepatic (CYP450), minimal clinical interactions

E. Available Brands

• Azelastine: Astepro, Rhinolast, Allergodil

• Olopatadine: Patanase

• Combination (with steroids): Dymista (azelastine + fluticasone)

F. Adverse Effects

• Bitter taste

• Nasal burning or irritation

• Epistaxis (nosebleed)

• Somnolence (rare)

• Headache

G. Contraindications and Cautions

• Hypersensitivity to active components

• Use with caution in patients with hepatic impairment

• Avoid concurrent alcohol or sedative use (due to minor CNS effects)

---

III. Nasal Decongestants

A. Mechanism of Action
Nasal decongestants are sympathomimetic agents that stimulate alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction. This leads to decreased blood flow, reduced edema, and improved nasal airflow.

B. Common Active Ingredients

1. Oxymetazoline hydrochloride

2. Xylometazoline hydrochloride

3. Phenylephrine hydrochloride

4. Naphazoline hydrochloride

C. Clinical Uses

• Nasal congestion due to:

  • Viral rhinitis (common cold)

  • Sinusitis

  • Allergic rhinitis

  • Vasomotor rhinitis

• Eustachian tube dysfunction

• Pre-operative nasal preparation

D. Pharmacokinetics

• Onset: 5–10 minutes

• Duration: 6–12 hours (longer for oxymetazoline, shorter for phenylephrine)

• Minimal systemic absorption when used appropriately

E. Available Brands

• Oxymetazoline: Afrin, Dristan, Zicam

• Xylometazoline: Otrivin, Nasenol

• Phenylephrine: Neo-Synephrine, Little Noses

• Naphazoline: Privine

F. Adverse Effects

• Rhinitis medicamentosa (rebound congestion with use >3–5 days)

• Nasal dryness

• Irritation or burning sensation

• Rare systemic effects: hypertension, palpitations, insomnia

G. Contraindications and Cautions

• Use >3 days is discouraged (due to rebound effects)

• Avoid in children <6 years unless advised by a physician

• Contraindicated in:

  • Severe hypertension

  • Coronary artery disease

  • Hyperthyroidism

  • Narrow-angle glaucoma

  • Concurrent use of MAO inhibitors

---

IV. Combination Nasal Antihistamines and Decongestants

Several combination formulations are available to leverage the synergistic effects of antihistamines (anti-allergy) and decongestants (vasoconstriction) for complete relief from allergic rhinitis or URTI-related nasal symptoms.

A. Example: Azelastine + Fluticasone (Dymista)

• Antihistamine + corticosteroid

• Indicated for moderate to severe allergic rhinitis

• Offers improved efficacy compared to either drug alone

B. Example: Antihistamine + Decongestant

• Fewer combinations are available intranasally compared to oral products

• Combination nasal sprays are sometimes compounded

---

V. Comparison: Nasal Antihistamines vs. Decongestants

Feature	Nasal Antihistamines	Nasal Decongestants
Primary action	H1 receptor blockade	Alpha-adrenergic vasoconstriction
Onset of action	15 minutes	5–10 minutes
Duration	12–24 hours (depends on drug)	6–12 hours
Ideal for	Allergic symptoms (sneezing, itching)	Nasal blockage, sinus pressure
Risk of rebound congestion	No	Yes (after >3 days of use)
Common side effects	Bitter taste, headache	Rebound rhinitis, dryness, HTN (rare)
Prescription status	Often Rx (e.g., azelastine)	Mostly OTC

VI. Administration Guidelines

1. Blow the nose gently before administration

2. Tilt head slightly forward (not backward)

3. Use opposite hand to opposite nostril for optimal spray angle

4. Avoid sniffing too hard—allow drug to settle on mucosa

5. Wait a few minutes before blowing nose again

6. For combination with other sprays (e.g., corticosteroids), use decongestant first, then antihistamine after 5–10 minutes

---

VII. Pediatric Use Considerations

• Decongestants not recommended in children <6 years (due to risks of systemic absorption and rebound effects)

• Antihistamines such as azelastine may be used in older children (age ≥6 years) with caution

• Always use pediatric-specific formulations

• Caregiver training on proper technique is crucial

---

VIII. Drug Interactions

Interacting Drug Class	Effect / Risk
Monoamine oxidase inhibitors	Potentiation of vasoconstrictive effects (HTN crisis risk)
Tricyclic antidepressants	Additive anticholinergic or cardiovascular effects
Sedatives / Alcohol	Additive CNS depression with antihistamines
Beta blockers	Masking of cardiovascular effects of nasal decongestants
CYP450 inhibitors	May alter metabolism of intranasal antihistamines

IX. Adverse Effects Monitoring and Risk Mitigation

A. Antihistamines

• Educate patients on bitter aftertaste—recommend saline rinse or mouthwash post-application

• Drowsiness: avoid driving or operating machinery initially

B. Decongestants

• Limit use to 3 consecutive days

• Monitor for rebound symptoms; transition to corticosteroids or saline irrigations if needed

• Advise against use in uncontrolled hypertensives or arrhythmic patients

---

X. Emerging Therapies and Innovations

• Second-generation nasal antihistamines with reduced systemic absorption and longer duration

• Metered-dose combination devices integrating antihistamines and steroids with improved tolerability

• Nasal antihistamine nanoparticles under development to enhance mucosal absorption

• AI-enabled delivery devices that optimize spray pressure and particle size

• Prophylactic use of antihistamine sprays before allergen exposure in seasonal allergies

---

XI. Counseling Points for Patients

• Do not use nasal decongestants for >3 consecutive days to avoid rebound congestion

• Store nasal sprays at room temperature and discard after 30–60 days of opening (per product labeling)

• Use a separate bottle per individual to avoid cross-contamination

• Prime the spray pump before first use (typically 3–4 sprays into air)

• Clean spray nozzle regularly to prevent clogging

---

XII. Conclusion

Nasal antihistamines and decongestants serve distinct but complementary roles in managing nasal symptoms arising from allergies and infections. Nasal antihistamines are optimal for allergic symptoms like sneezing and itching, while decongestants provide rapid relief from nasal obstruction. Proper administration, short-term use of decongestants, and integration into broader therapeutic regimens including corticosteroids or saline irrigations are critical to achieving optimal patient outcomes.